Foritinib in advanced ROS1-rearranged NSCLC in China
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a recent paper titled “Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study” published in The Lancet.
Authors: Prof Jin-Ji Yang, Prof Jianying Zhou, Prof Si-Yang Maggie Liu, Mingjun Li, Prof Zhiye Zhang, Prof Ying Cheng, Prof Yun Fan, Prof Hongming Pan, Baoqing Wang, Prof Gongyan Chen, Prof Ke Wang, Prof Liyan Jiang, Yanping Hu, Prof Jianhua Shi, Prof Xiaorong Dong, Prof Cuimin Ding, Prof Yunpeng Liu, Prof Zhe Liu, Prof Wangjun Liao, Prof Wei Li, Prof Jun Wang, Prof Shanyong Yi, Prof Qiong Zhao, Prof Aimin Zang, Prof Yuan Chen, Prof Jiuwei Cui, Prof Pengfei Luo, Prof Xionghu Shen, Prof Meili Sun, Prof Changli Wang, Prof Yi-Long Wu.
“Foritinib in advanced ROS1-rearranged NSCLC in China: phase II single-arm study.
In phase 2a, the ORR was 94% and the cranial RR was 100% in inhibitor-naive patients. In phase 2b, the ORR was 88% and the cranial RR was 90%.”
Source: Yakup Ergün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023